Abbott Laboratories (ABT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $190.97B
Last updated: Sep 01, 2026 at 5:00 PM ET
Earnings
Performance (10Y)
Upcoming Estimates
Dividends
Dividend Metrics
Growth
Key Metrics
Technical Indicators Dashboard
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Data
Related GNG Research
Abbott: The Market Priced the Dent and Forgot the Cargo
Market punished Abbott - stock down ~34% from 52-week high $139.06 to ~$91, yet TTM revenue $45.1B, gross margin 56.4%, operating cash flow $9.46B and free cash flow $7.38B ($4.22/sh, 4.85% FCF yield) Closed oncology acquisition for ~$21B equity (~$23B incl assumed debt), funded with $20B notes, net debt ~ $27B, trims ~ $0.20 of adjusted EPS this year while adding ~$3B sales into a ~$60B oncology screening market FDA warning letter and Class I recall relate to CGM manufacturing controls, but regulators did not halt shipments - analysts expect limited near-term reported impact while Abbott completes corrective actions Dividend and balance-sheet intact - 50+ years of increases, quarterly $0.63 ($2.52/year) equals ~2.8% yield, payout ~45% of adjusted earnings, interest coverage >30x, Altman 2.97, Beneish indicates no manipulation Market pricing implies ~1.6% perpetual cash-flow growth versus management organic guide 6.5%-7.5%; blended fair value ~$112.50 implies 19% margin of safety and ~14% 12-month total return including the dividend
Intuit (INTU): The Stock Broke Before the Business Did
INTU down ~56% to ~$331 from >$800, trading well below the 200-day at $554 - thesis: market priced collapse, but business intact; staged Strong Buy, blended fair value $480, 12-month target $430, margin of safety ~31% Buy schedule - start a partial near $331, add on a defended retest low $300s, commit final tranche after reclaiming mid-$360s and the $385-$405 confirmation zone, position size 1% to 2% per name Quality metrics - trailing 12-month FCF ~$7.7B on $20.9B revenue (FCF margin ~37%), gross margin ~80%, net margin ~22%, ROIC high teens (≈35% cash basis), net debt <0.1x equity, Altman Z 4.93, Piotroski 9 Growth drivers - FY26 revenue guidance $21.341B-$21.374B (+13%-14%), non-GAAP EPS ~+18%; segment strength: QuickBooks/Global Business Solutions +15%, Online Ecosystem +19%, Credit Karma +15%, Consumer +8% Key risks and valuation - TurboTax low-end vulnerable to free AI and share loss, 17% workforce cut with $300M-$340M charges; stock trades ~12x forward EPS and FCF, FCF yield >8%, market implies ~1% FCF CAGR over 5 years
The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now
(MDT) has raised its dividend for 48 consecutive years, yet trades at just 14x forward earnings. On a trailing basis it is 24x vs. (ISRG) at 57x and (SYK) at 40x. The 5-year dividend CAGR is 4.4%, slowing to 2.0% over three years. This is a yield anchor at 3.3%, not a fast compounder. Payout ratio of 50.2% keeps the streak sustainable. FCF yield sits near 4.87% with $5.41B in trailing free cash flow. Ten straight years of positive FCF. The income is backed by real cash generation. Revenue grew 8.7% in the most recent quarter, the company's strongest enterprise growth in 10 quarters. Full-year guidance raised then reiterated. Two consecutive beats matter. Blended fair value from multiple sources lands near $107-$108 vs. current price near $86, implying roughly 24-25% upside before the 3.3% yield. GNG Research internal FV is $94.01. EPS beat rate over the last 8 quarters: 100%. The market is pricing this like a business that disappoints. The data from the GNG Research terminal shows otherwise.
Why TransMedics Stock is a Buy for Long-Term Investors
TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash: $250K consoles + $80–100K per-procedure recurring revenue + the scaling National OCS Program (NOP) aircraft fleet. Margins expanding, FCF inflection is real. Financials are inflecting sharply: EPS beat (+83%), strong operating leverage, rising gross margins, and guidance moving higher even with temporary revenue noise. Short-term volatility ≠ broken thesis: Stock recently sold off on a slight revenue miss and high short interest, but fundamental adoption trends remain strong across transplant centers. Long-term runway is substantial: Multi-organ expansion, NOP scaling, higher utilization rates, and future indications (including kidney) create years of growth. GNG Research Rating — BUY on weakness: Best accumulation zone is sub-$110, with long-term fair value well above current levels based on sustained growth, rising margins, and expanding TAM.
Government Contracts
Top agency: Department of Veterans Affairs at 64.8% of trailing twelve month obligations across 10 agencies
Recent Awards
Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.
News
Frequently Asked Questions About ABT
- What is ABT's current dividend yield?
- Abbott Laboratories (ABT) has a current dividend yield of 2.25%.
- Does ABT pay dividends?
- Yes, Abbott Laboratories pays dividends with a current yield of 2.25%.
- What is ABT's P/E ratio?
- Abbott Laboratories has a price-to-earnings (P/E) ratio of 20.98.
- What is ABT's market cap?
- Abbott Laboratories (ABT) has a market capitalization of $190.97B with a current stock price of $110.34.
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.